UBX unitybiotechnology.com Earnings per share growth rate in current year
Unity Biotechnology (UBX) management is adapting clinical plans to fit a tight budget, which gives the asset a speculative status. The development of senolytic agents for brain and eye therapy diversifies risks. Annual EPS progress demonstrates earnings per share dynamics, where the value is fixed at 42.90. The implementation of zero-waste laboratory technologies and water conservation confirms the company's commitment to environmental synthesis standards.
Financial and market metric breakdowns for Unity Biotechnology (UBX)
- current quotes and average value forecast:
- market capitalization data:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Equity Ratio Unity Biotechnology|UBX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital unitybiotechnology.com|UBX - Company Debts|Debt to Book Value Ratio Unity Biotechnology, Inc|UBX - Company Long-Term Debt|Short-Term Debt Unity Biotechnology|Quick Liquidity unitybiotechnology.com
- earnings and valuation multiples indicators:
UBX - Company Net Income|Expected Net Profit Unity Biotechnology|UBX - P/E Multiple|Forward Price to Earnings Multiple Unity Biotechnology, Inc|UBX - Price/Earnings to Growth Multiple|Company Value to EBITDA Unity Biotechnology, Inc|UBX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Unity Biotechnology|UBX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months unitybiotechnology.com|UBX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Unity Biotechnology
Basic company analysis:Unity Biotechnology Inc.
Assessing profit capitalization rates is critical for identifying fundamental leaders within the biotech sector. This indicator measures the percentage change in earnings per share (EPS) compared to the previous year, reflecting market expectations regarding cost management efficiency. For Unity Biotechnology (UBX), which invests in retaining rare geneticists through R&D, current annual EPS growth serves as a marker of how effectively science-intensive developments are converting into financial results.
Main competitors
TEM - Expected net earnings per share growth this year|Earnings per share growth in current year Qiagen Group|Earnings per share growth rate in current year Isis Pharmaceuticals IONS|Net earnings per share growth this year RGEN (Repligen Corporation)|Net earnings per one share growth for the current year RNA|Earnings growth in current year CRSP (CRISPR Therapeutics)|GeneDx Holdings (WGS) - Earnings per share growth rate in current year|Ultragenyx Pharma - Earnings growth in current year|Beam Tx (BEAM) - Net earnings per share growth this year|SRPT: Earnings growth in current year|twistbioscience.com - Earnings per share increase in current year|Earnings per share growth in current year 10x Genomics|Earnings per share growth this year NTLA (Intellia Therapeutics Inc)|Earnings per share growth in current year Stoke (STOK)|BLFS - Earnings per share growth rate in current year|Earnings per share growth in current year Wave Life Sciences WVE|mazetx.com - Earnings per share growth in current year|SION - Earnings per share growth in current year|Earnings per share growth rate in current year Prime Medicine Inc|TSHA: Earnings growth in current year|Net earnings per share change in current year uniQure Pharma QURE|Net earnings per share growth this year MGTX|Earnings per share growth rate in current year regenxbio.com RGNX|Net earnings per share growth this year SLDB (Solid Biosciences)|Earnings growth in current year Ocugen Inc (OCGN)|Earnings growth in current year PACB (Pacific Biosciences of California)|Benitec Corp - Earnings per share growth in current year|DSGN: Net earnings per share growth this year|RCKT (rocketpharma.com) - Earnings per share growth this year|FDMT: Earnings growth in current year|Earnings per share growth this year LXEO|Earnings per share growth in current year Korro Bio Inc.|Earnings per share growth this year EDIT (Editas Corp)|Earnings growth in current year SLN|Earnings growth in current year proqr.com (PRQR)|Codexis - Net earnings per share growth this year|Earnings growth in current year Sangamo Therapeutics Inc. SGMO|NAUT - Earnings per share growth in current year|MGX (Metagenomi Therapeutics) - Earnings per share growth this year|DTIL: Earnings growth in current year|GBIO - Expected net earnings per share growth this year|Net earnings per share growth this year BOLD|XCUR (Exicure Corp) - Net earnings per one share growth for the current year|Net earnings per share growth this year IMNN (Imunon, Inc.)|PHIO - Earnings per share growth rate in current year|Mustang Bio - Net earnings per share growth this year|Earnings per share increase in current year RNAZ|Bionano - Earnings growth in current year|APDN: Earnings per share growth in current year|BLUE: Earnings growth in current year|IPA - Expected net earnings per share growth this year|Earnings per share growth in current year Omega Therapeutics|Earnings per share growth rate in current year singulargenomics.com OMIC|Net earnings per share growth this year RGLS (Regulus Therapeutics Inc.)|Net earnings per one share growth for the current year SYRS|Earnings growth in current year TBIO (Codex DNA)|TRACON Pharmaceuticals, Inc (TCON) - Earnings per share growth rate in current year
